MedTrace Logo

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

NCT00317694 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2009-08-10

No results posted yet for this study

Summary

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.

The purpose of this study it to look at how effective and safe Magnesium iron hydroxycarbonate is in controlling levels of phosphate in the blood in patients who receive hemodialysis.

Conditions

  • Chronic Kidney Failure

Interventions

DRUG

Fermagate

Film coated tablet 500mg

DRUG

Placebo

Oral administration, film coated tablet, 0mg

Sponsors & Collaborators

  • Ineos Healthcare Limited

    lead INDUSTRY

Principal Investigators

  • Simon Roe, MB ChB · Nottingham Renal and Transplant Unit, Nottingham City Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00317694 on ClinicalTrials.gov